Brett Wadsworth
Psychiatric/Mental Health · Issaquah, WANPI 1649727249
Payments from drug & device makers
Across 160 payments — averaging $17.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$649
- Supernus Pharmaceuticals, Inc.$440
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$428
- Eisai Inc.$180
- Alkermes, Inc.$163
- Lundbeck LLC$147
- plus $791 from 10 others
What the payments were for
- Food & beverage$2,74098%
- Education$572%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 37 | $649 |
| Supernus Pharmaceuticals, Inc. | 31 | $440 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 23 | $428 |
| Eisai Inc. | 15 | $180 |
| Alkermes, Inc. | 8 | $163 |
| Lundbeck LLC | 6 | $147 |
| Johnson & Johnson | 7 | $145 |
| Tris Pharma Inc | 8 | $143 |
| Corium, LLC | 7 | $142 |
| Bausch Health US, LLC | 6 | $117 |
| Otsuka America Pharmaceutical, Inc. | 5 | $100 |
| Neurocrine Biosciences, Inc. | 2 | $44 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $43 |
| Jazz Pharmaceuticals Inc. | 1 | $24 |
| Adlon Therapeutics L.p. | 1 | $20 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
How this compares
$2,797 in reported general payments places this provider in the 90th percentile of 931 psychiatric/mental health providers in Washington.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 12 | $17,078 |
| VyvanseLisdexamfetamine Dimesylate | 13 | $4,995 |
| Lisdexamfetamine Dimesylate | 19 | $3,922 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 16 | $669 |
| Bupropion XlBupropion Hcl | 21 | $244 |
| Lamotrigine | 27 | $185 |
| Duloxetine Hcl | 13 | $130 |
| Zolpidem Tartrate | 14 | $118 |
| Quetiapine Fumarate | 19 | $98 |
| Aripiprazole | 11 | $96 |
| Escitalopram Oxalate | 16 | $55 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $649 | $17,07812 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $43 | $4,99513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 931 psychiatric/mental health providers in Washington.
Other psychiatric/mental health in Issaquah
- Angela CombsRichland$121K
- Ashley McGinnisAuburn$26K
- Courtney YantPuyallup$26K
- Dawn MasonSpokane$25K
- Janine TorresAuburn$24K
- Jennifer WilsonYakima$23K
- Patricia MorganKirkland$21K
- Kojo SarfoEllensburg$20K
- Brendan RoeVancouver$18K
- Jenna VoKent$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.